This site is intended for health professionals only

At the heart of general practice since 1960

Read the latest issue online

CAMHS won't see you now

Paper of the Day - Basal-bolus insulin preferred after glargine

Patients with type 2 diabetes are more likely to hit a HbA1c target of 7% if they move on to a basal/bolus therapy – rather than prandial premixed therapy – after initial treatment with glargine.

US researchers randomly assigned 374 patients previously treated with glargine plus oral agents to receive either bedtime glargine plus mealtime lispro or 50/50 lispro mix three times a day with meals.

After 24 weeks average HbA1c was lower with the basal/bolus regime – 6.78% versus 6.95% with the prandial premixed. Significantly more patients achieved a target of less than 7% with the basal/bolus therapy – 69% versus 54%. But the difference was not significant for 6% or 7.5% targets. Rates of hypoglycamia were similar for both groups.

The authors say that although noninferiority of prandial premixed therapy to basal/bolus therapy was not demonstrated, findings for HbA1c reduction, percentage of patients achieving HbA1c targets, hypoglycemia, and number of required injections should be considered in the individual decision-making process of advancing insulin replacement in type 2 diabetes

Diabetes Care 2008; 31: 20-25.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say